Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(267)
•••
Comment by LaserStock29on Aug 01, 2020 10:14pm
203 Views
Post# 31354723

RE:RE:RE:RE:RE:RE:RE:RE:RE:Theralase = TLD-1433

RE:RE:RE:RE:RE:RE:RE:RE:RE:Theralase = TLD-1433
Enriquesuave.. those questions might have been relevant in 2014...  These issues were discussed now for 10 years... and we have the doctors since running the photofrin trial from 1993... so whatever happend it happened.. and 2m volume was gifted to particular parties who didn't want them at $1 or higher IMO.

Heck maybe if we got a 'complete' report with 58% CR  and find out all 3 patients have upper tract seeding thus not originating in the bladder organ our pps would of shot up too.

I absolutely DETEST the INCOMPLETE nature of this REPORT.   it screams to me bad taste.


Im real sick of this buttering bread.. we'll get there in the end.. all will be there in the end... STOP SAYING THAT.


we know TWO ENDPOINTS.

Health Canada 2022 with their Fast Track application getting drugs to patients i posted the link long time ago.

Then there was the 2020 what will this company do to get the pps at $2 bucks.

Theres the GBM by Dr Mandel with the non-gmp and gmp and theres now this absolutely bullish Roswell NSCLC and Mesoth potential thanks to talks Dr.McFarland has been having.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities